PRIP Scheme: India Backs 41 Pharma, MedTech R&D Projects
PRIP scheme: India approved about ₹1,600 crore for 41 pharma and MedTech R&D projects, expected to draw ₹3,020 crore more in private investment.
PRIP scheme: India approved about ₹1,600 crore for 41 pharma and MedTech R&D projects, expected to draw ₹3,020 crore more in private investment.
FHD-909 discontinued: Foghorn and Lilly will not advance the SMARCA2 inhibitor after Phase 1 data, and Foghorn is cutting about 40% of its workforce.
Survodutide weight loss reached up to 13.1% versus 3.1% on placebo at 76 weeks in the Phase III SYNCHRONIZE-2 trial in people with type 2 diabetes.
Trevogrumab added to semaglutide cut lean muscle loss in Regeneron's nearly 1,000-patient trial, preserving over 70% of thigh muscle at 52 weeks.
Yutrepia patent ruling: a Delaware court found Liquidia's Yutrepia infringes two valid United Therapeutics patent claims, and Liquidia shares plunged.